Camila Pachêco Gomes

Camila Pachêco Gomes

Auto-generated profile, based on publicly available information

Camila Pachêco Gomes

Department of Microbiology, Universidade Estadual de Santa Cruz, Ilheús, BA, Brazil

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2024 in Einstein (São Paulo)
Verified
Journal Article
Open access
PDF file
HFHenrique Andrade Fonseca
Henrique Andrade Fonseca
APAdriano Jose Pereira
Adriano Jose Pereira
RNRicardo Kenji Nawa
Ricardo Kenji Nawa
VSViviane Aparecida Rodrigues Sant’aNna
Viviane Aparecida Rodrigues Sant’aNna
TATatiana Ferreira de Almeida
Tatiana Ferreira de Almeida
OBOtávio Berwanger
Otávio Berwanger
Highlights Previous influenza vaccination was associated with a reduced need for hospitalization after COVID-19 diagnosis. In 60 days of outpatient setting, four deaths occurred (three in the hospitalized and one in the non-hospitalized group). The persistence of more than two symptoms in 60 days was observed in 31.9% of patients. ABSTRACT Objective: To evaluate deaths, hospitalizations, and persistence of symptoms in patients with COVID-19 after infection in an outpatient setting during the first COVID-19 wave in Brazil. Methods: This prospective

21 July 2022 in Research, Society and Development
Verified
Journal Article
Open access
PDF file
LSLucas Santana Coelho da Silva
Lucas Santana Coelho da Silva
Caroline Tianeze de CastroCaroline Tianeze de Castro
Caroline Tianeze de Castro
CGCamila Pachêco Gomes
Camila Pachêco Gomes
MJMANOEL NERES SANTOS JUNIOR
MANOEL NERES SANTOS JUNIOR
Maysa Santos BarbosaMaysa Santos Barbosa
Maysa Santos Barbosa
LMLucas Miranda Marques
Lucas Miranda Marques
The present systematic review and meta-analysis aimed to investigate the use of recombinant proteins to diagnose STIs and evaluate the performance of the tests identified. The databases, SciELO, PubMed, CAPES Journal Portal, and LILACS, were searched according to the PRISMA protocol. A study was considered eligible if it met previously defined criteria. The risk of study bias was assessed according to the QUADAS-2 protocol. The meta-analysis was performed based on the random-effects model, and heterogeneity was quantified using the I² statistic. A total of 1,355 studies were selected, 30 of which were relevant to the following: human immunodeficiency virus (12/30), Treponema pallidum (10/30), Chlamydia trachomatis (3/30), herpes simplex virus (HSV, 2/30), Trichomonas vaginalis (2/30), and HSV/cytomegalovirus (1/30). The main serological tests were ELISA and immunochromatography. The risk of bias was low for most included studies. According to each microorganism, the meta-analysis revealed satisfactory sensitivity and specificity for the analyzed tests. The findings reinforce the relevance of diagnostic tests based on recombinant proteins as viable alternatives for production and inclusion in clinical practice. PROSPERO registration number: CRD42020206331.